Can we eliminate placebo in ALS clinical trials?

Research output: Contribution to journalComment/debate

7 Citations (Scopus)

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal disease with limited treatment options. Controlled studies are a necessary part of Phase II and Phase III assessments of proposed therapies. Due to the relatively small number of patients with ALS, several study designs have been proposed to improve the efficiency of Phase II studies. Some of these advocate the use of historical controls in place of placebo controls. However, the characteristics of historical controls may not mirror those of patients in the treatment group. Novel study designs can be used to decrease the number of patients required for Phase II studies. The use of placebo controls rather than historical controls in these novel study designs likely leads to better predictions of treatments that will be successful in Phase III studies. There is general agreement on the necessity of placebo controls in Phase III studies.

Original languageEnglish (US)
Pages (from-to)861-865
Number of pages5
JournalMuscle and Nerve
Volume39
Issue number6
DOIs
StatePublished - Jun 1 2009

Fingerprint

Amyotrophic Lateral Sclerosis
Placebos
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

@article{0bf7cc1652de4145a4866e50daf457cc,
title = "Can we eliminate placebo in ALS clinical trials?",
abstract = "Amyotrophic lateral sclerosis (ALS) is a fatal disease with limited treatment options. Controlled studies are a necessary part of Phase II and Phase III assessments of proposed therapies. Due to the relatively small number of patients with ALS, several study designs have been proposed to improve the efficiency of Phase II studies. Some of these advocate the use of historical controls in place of placebo controls. However, the characteristics of historical controls may not mirror those of patients in the treatment group. Novel study designs can be used to decrease the number of patients required for Phase II studies. The use of placebo controls rather than historical controls in these novel study designs likely leads to better predictions of treatments that will be successful in Phase III studies. There is general agreement on the necessity of placebo controls in Phase III studies.",
author = "Zachary Simmons",
year = "2009",
month = "6",
day = "1",
doi = "10.1002/mus.21358",
language = "English (US)",
volume = "39",
pages = "861--865",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

Can we eliminate placebo in ALS clinical trials? / Simmons, Zachary.

In: Muscle and Nerve, Vol. 39, No. 6, 01.06.2009, p. 861-865.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Can we eliminate placebo in ALS clinical trials?

AU - Simmons, Zachary

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Amyotrophic lateral sclerosis (ALS) is a fatal disease with limited treatment options. Controlled studies are a necessary part of Phase II and Phase III assessments of proposed therapies. Due to the relatively small number of patients with ALS, several study designs have been proposed to improve the efficiency of Phase II studies. Some of these advocate the use of historical controls in place of placebo controls. However, the characteristics of historical controls may not mirror those of patients in the treatment group. Novel study designs can be used to decrease the number of patients required for Phase II studies. The use of placebo controls rather than historical controls in these novel study designs likely leads to better predictions of treatments that will be successful in Phase III studies. There is general agreement on the necessity of placebo controls in Phase III studies.

AB - Amyotrophic lateral sclerosis (ALS) is a fatal disease with limited treatment options. Controlled studies are a necessary part of Phase II and Phase III assessments of proposed therapies. Due to the relatively small number of patients with ALS, several study designs have been proposed to improve the efficiency of Phase II studies. Some of these advocate the use of historical controls in place of placebo controls. However, the characteristics of historical controls may not mirror those of patients in the treatment group. Novel study designs can be used to decrease the number of patients required for Phase II studies. The use of placebo controls rather than historical controls in these novel study designs likely leads to better predictions of treatments that will be successful in Phase III studies. There is general agreement on the necessity of placebo controls in Phase III studies.

UR - http://www.scopus.com/inward/record.url?scp=67049096146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67049096146&partnerID=8YFLogxK

U2 - 10.1002/mus.21358

DO - 10.1002/mus.21358

M3 - Comment/debate

C2 - 19382170

AN - SCOPUS:67049096146

VL - 39

SP - 861

EP - 865

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 6

ER -